PHASE I/IB STUDY OF NK EXPRESSING AN AFFINITY-ENHANCED T-CELL RECEPTOR (TCR) AGAINST THE NY-ESO-1
This is an open-label phase 1 study to determine how well NY-ESO-1 TCR/IL-15 NK is tolerated, its safety, and the dose range in patients with relapsed/refractory synovial sarcoma or myxoid/round cell liposarcoma, who have undergone at least one prior line of therapy involving doxorubicin and/or ifosfamide. NY-ESO-1 TCR/IL-15 NK is a cell therapy that uses natural killer cells from cord blood to mount an immune response in the body to treat sarcoma. Before receiving the NY-ESO-1 TCR/IL-15 NK dose, patients undergo a process to deplete existing T-cells, setting the stage for the new therapy.
Over the following 12 months, twelve scheduled visits to the study doctor will be required, with most appointments expected to occupy a whole day for standard sarcoma-related testing. Patient support services provided for travel for the appointments.
Clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06083883?cond=synovial%20sarcoma&term=TCR-NK&rank=1